Solana'nın önerdiği enflasyon modeli değişiklikleri SOL fiyatlarının daha da yükselmesine yardımcı olabilir mi?

Anthera Pharmaceuticals

company

About

Anthera Pharmaceuticals is focused on developing products to treat diseases associated with inflammation and autoimmune diseases.

  • 1 - 10

Details

Last Funding Type
Post-IPO Debt
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2004
Number Of Employee
1 - 10
Operating Status
Active

Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies for the treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$55M
Anthera Pharmaceuticals has raised a total of $55M in funding over 2 rounds. Their latest funding was raised on Jan 1, 2011 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 1, 2011 Post-IPO Debt 1 Detail
Aug 14, 2008 Series Unknown $19M 1 Caxton Advantage Life Sciences Fund Detail
Sep 13, 2006 Series Unknown $36M 2 Detail

Investors

Number of Lead Investors
Number of Investors
1
4
Anthera Pharmaceuticals is funded by 4 investors. Caxton Advantage Life Sciences Fund and Hercules Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Caxton Advantage Life Sciences Fund Yes Series Unknown
Hercules Capital Post-IPO Debt
SIM Equity Series Unknown
Sears Capital Management Series Unknown